Prosecution Insights
Last updated: November 15, 2026

Avectas Limited

Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials

5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready

Analysis

Avectas Limited has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 5 distinct examiners across 3 distinct art units, indicating broad examiner distribution with multiple matters sharing art-unit settings. HENKEL, DANIELLE B is the busiest examiner, with 1 pending matter.

The assignment pattern supports a coordinated portfolio record combined with examiner-specific prosecution tactics. Counsel should compare objections within each art unit, then evaluate whether differences arise from examiner practice or from the claims and disclosures in the individual files. The matter before HENKEL, DANIELLE B is the identified examiner focus, but the distribution means that no single response strategy can be assumed to govern every pending matter.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

5
Total Pending OAs
3
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (40%)
2
Medium (40%)
1
Easy (20%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (20%)
§103 only1 (20%)
§112 only1 (20%)
Double-patenting + other1 (20%)
Multi-statute (no §101)1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
80% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
20% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HENKEL, DANIELLE B 1 56.4% +23.4%
MCKILLOP, JOHN CHARLES 1 59.6% +42.7%
LEVIN, JOEL D 1 58.0% +33.8%
WESTON, ALYSSA G 1 59.2% +50.7%
BOWERS, NATHAN ANDREW 1 59.7% +31.4%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18272699 SEQUENTIAL DELIVERY OF RNPS TO IMMUNE CELLS MCKILLOP, JOHN CHARLES 22d overdue
18760260 VECTOR-FREE INTRACELLULAR DELIVERY BY REVERSIBLE PERMEABILISATION HENKEL, DANIELLE B —

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18272699 SEQUENTIAL DELIVERY OF RNPS TO IMMUNE CELLS MCKILLOP, JOHN CHARLES 22d overdue
16841093 DELIVERY ACROSS CELL PLASMA MEMBRANES BOWERS, NATHAN ANDREW 11d overdue
17012748 ENGINEERING OF IMMUNE CELLS FOR EX VIVO CELL THERAPY APPLICATIONS WESTON, ALYSSA G 15d
18760260 VECTOR-FREE INTRACELLULAR DELIVERY BY REVERSIBLE PERMEABILISATION HENKEL, DANIELLE B —
17615081 METHODS OF VIRAL DELIVERY TO A POPULATION OF CELLS LEVIN, JOEL D —

Top Art Units

Art UnitApps
1633 2
1637 1
1799 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18760260 VECTOR-FREE INTRACELLULAR DELIVERY BY REVERSIBLE PERMEABILISATION HENKEL, DANIELLE B — §102§103Other Non-Final OA — Pending Jul 01, 2024
18272699 SEQUENTIAL DELIVERY OF RNPS TO IMMUNE CELLS MCKILLOP, JOHN CHARLES 1637 §101§102§112Other Final Rejection 22d overdue Pending Jul 17, 2023
17615081 METHODS OF VIRAL DELIVERY TO A POPULATION OF CELLS LEVIN, JOEL D 1633 §103 Non-Final OA — Pending Nov 29, 2021
17012748 ENGINEERING OF IMMUNE CELLS FOR EX VIVO CELL THERAPY APPLICATIONS WESTON, ALYSSA G 1633 §112 Final Rejection 15d Pending Sep 04, 2020
16841093 DELIVERY ACROSS CELL PLASMA MEMBRANES BOWERS, NATHAN ANDREW 1799 §103DP Non-Final OA 11d overdue Pending Apr 06, 2020

Managing Avectas Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Avectas Limited have?

Avectas Limited has 5 pending office actions as of November 2026, spread across 3 art units and 5 examiners.

Which USPTO examiner handles the most Avectas Limited applications?

Danielle B Henkel has the most, with 1 of Avectas Limited's pending office actions.

What technology area are Avectas Limited's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month